Payment overview · 2025
General Payments
$3,087.98
172 reported records · 24 companies
Healthcare provider profile · identity verified
William John Leahy, MD
Allopathic & Osteopathic Physicians|Family Medicine · LIMA, OH · NPI 1447245774
Verified facts
What the public records show
CMS Open Payments records show William John Leahy, MD received $3,087.98 in general payments during 2025 across 172 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $669.17 | 21.7% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $612.85 | 19.9% | 38 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $355.34 | 11.5% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $241.30 | 7.8% | 18 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $173.40 | 5.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.67 | 4.6% | 11 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $122.12 | 4.0% | 6 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $99.82 | 3.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.14 | 2.8% | 4 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.38 | 2.3% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $62.51 | 2.0% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $55.66 | 1.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.02 | 1.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.12 | 1.7% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $50.48 | 1.6% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.39 | 1.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.10 | 1.6% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.75 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.10 | 0.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.95 | 0.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.82 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.46 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.00 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,087.98 | 172 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $482.82 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $432.20 | 24 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $234.10 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $226.87 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $194.87 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $184.85 | 14 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $177.82 | 13 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $173.40 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $170.49 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $168.42 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $144.44 | 11 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $137.31 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $122.12 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.99 | 11 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $99.82 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.45 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.45 | 7 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $71.38 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $62.51 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.22 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $55.66 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $55.66 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.02 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $53.12 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $48.39 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.95 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 911 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 125 |
| Lisinopril | Lisinopril | 475 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 115 |
| Omeprazole | Omeprazole | 415 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 111 |
| Losartan Potassium | Losartan Potassium | 350 | 93 |
| Metformin Hcl | Metformin Hcl | 310 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 85 |
| Metformin Hcl Er | Metformin Hcl | 280 | 77 |
| Sertraline Hcl | Sertraline Hcl | 258 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 57 |
| Simvastatin | Simvastatin | 194 | 54 |
| Gabapentin | Gabapentin | 177 | 44 |
| Allopurinol | Allopurinol | 162 | 44 |
| Meloxicam | Meloxicam | 160 | 52 |
| Alprazolam | Alprazolam | 155 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 32 |
| Azithromycin | Azithromycin | 150 | 116 |
| Tramadol Hcl | Tramadol Hcl | 150 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 38 |
| Ozempic | Semaglutide | 145 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 144 | 41 |
| Glipizide Er | Glipizide | 140 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 140 | 37 |
| Famotidine | Famotidine | 134 | 28 |
| Synthroid | Levothyroxine Sodium | 134 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 58 |
| Trazodone Hcl | Trazodone Hcl | 118 | 30 |
| Eliquis | Apixaban | 114 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 26 |
| Buspirone Hcl | Buspirone Hcl | 95 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 25 |
| Furosemide | Furosemide | 90 | 20 |
| Prednisone | Prednisone | 88 | 63 |
| Ramipril | Ramipril | 88 | 22 |
| Atenolol | Atenolol | 85 | 19 |
| Warfarin Sodium | Warfarin Sodium | 85 | suppressed |
| Ezetimibe | Ezetimibe | 82 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 18 |
| Potassium Chloride | Potassium Chloride | 72 | 21 |
| Jardiance | Empagliflozin | 68 | 17 |
| Cefdinir | Cefdinir | 67 | 54 |
| Donepezil Hcl | Donepezil Hcl | 66 | 18 |
| Montelukast Sodium | Montelukast Sodium | 66 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 46 |
| Farxiga | Dapagliflozin Propanediol | 59 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 11 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 23 |
| Methylprednisolone | Methylprednisolone | 55 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 12 |
| Glipizide | Glipizide | 52 | 14 |
| Glimepiride | Glimepiride | 50 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 49 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 13 |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Fenofibrate | Fenofibrate | 45 | 14 |
| Cephalexin | Cephalexin | 44 | 37 |
| Finasteride | Finasteride | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 14 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Carvedilol | Carvedilol | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 40 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 25 |
| Paroxetine Er | Paroxetine Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Eszopiclone | Eszopiclone | 35 | 13 |
| Ondansetron Odt | Ondansetron | 35 | 25 |
| Testosterone | Testosterone | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | suppressed |
| Nystatin | Nystatin | 34 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 14 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 17 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Armour Thyroid | Thyroid,pork | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Lovastatin | Lovastatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Promethegan | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,087.98 · 172 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ANDEXXA, Auvelity, Azstarys, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Jornay PM, MOUNJARO, OPSUMIT, OTEZLA, Omnipod, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tlando, UBRELVY, UNITHROID, UPTRAVI, VIVITROL, VOQUEZNA, VRAYLAR, WAKIX, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error